Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study

Diabetes Technology and Therapeutics

Volumn 14, Issue 7, 2012, Pages 644-647

  Buse, John B ^a   Kudva, Yogish C ^b   Battelino, Tadej ^c   Davis, Stephen N ^d   Shin, John ^e   Welsh, John B ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ARTICLE; BIOSENSOR; CONTROLLED STUDY; DRUG THERAPY; GLUCOSE BLOOD LEVEL; GLYCEMIC VARIABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; MULTIPLE DAILY INJECTION THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSOR AUGMENTED PUMP THERAPY;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863795397     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0294     Document Type: Article

References (19)

1. Monnier L, Colette C, Owens D: The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 2012;95:303-311
2. Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181
3. Cameron FJ, Baghurst PA, Rodbard D: Assessing glycemic variation: why, when and how? Pediatr Endocrinol Rev 2010;7(Suppl 3):S432-S444
4. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320
5. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA: Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 2011;34:2403-2405
6. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV: STAR 3 randomized controlled trial
7. Peyrot M, Rubin RR, Chen X, Frias JP: Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13:471-476
8. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C: Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011;10:19
9. Monnier L, Wojtusciszyn A, Colette C, Owens D: The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818
10. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708
11. Patton SR, Midyett LK, Dolan LM, Powers SW: A comparison of average daily risk range scores for young children with type 1 diabetes mellitus using continuous glucose monitoring and self-monitoring data. Diabetes Technol Ther 2012;14:239-243
12. Bao YQ, Zhou M, Zhou J, Lu W, Gao YC, Pan XP, Tang JL, Lu HJ, Jia WP: Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Clin Exp Pharmacol Physiol 2011;38:50-54
13. Alghothani N, Dungan KM: The effect of glycemic variability on counterregulatory hormone responses to hypoglycemia in young children and adolescents with type 1 diabetes. Diabetes Technol Ther 2011;13:1085-1089
14. Rizvi M, Pathak D, Freedman JE, Chakrabarti S: CD40- CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008;14:530-538.
15. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Yuksel F, Sisman AR, Yesil S: Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 2010;59:305-313
16. Peters AL, Stunz LL, Bishop GA: CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009;21: 293-300
17. Lajer M, Tarnow I, Michelson AD, Jorsal A, Frelinger AL, Parving HH, Rossing P, Tarnow L: Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets 2010;21:525-532
18. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM: Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 2010;33: 1591-1597
19. Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN:The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2011;34:177-180